Skip to content
Strength & muscleResearch article3 min read

Genetically lower vitamin D below 20 ng/mL linked to higher sarcopenia risk in UK adults

MoveVitals Editorial Collective · Study published · Reading updated

Original paper:Genetic Variants, Serum 25-Hydroxyvitamin D Levels, and Sarcopenia: A Mendelian Randomization Analysis. · JAMA network open · 2023 · Original paper ↗

Key takeaway

In 295,489 UK Biobank adults, genetically predicted vitamin D below 20 ng/mL was linked to higher sarcopenia risk (odds ratio 1.74 for 10 vs 20 ng/mL; 95% CI 1.17-2.59), with no further benefit above 20 ng/mL. Mendelian randomization reduces confounding but rests on assumptions, and the authors say trials are needed to confirm causality.

Study design

Research article

Reading basis

Published abstract

Reading focus

Design & applicability

The research question

Guidelines do not recommend vitamin D supplements for sarcopenia (age-related muscle loss) when levels are already adequate, but about 30% of the world's population sits between 10 and 20 ng/mL, a range whose health meaning is unclear. The authors asked whether these suboptimal levels are linked to sarcopenia risk.

Who and how

Genetic association study using nonlinear and standard mendelian randomization, performed from August 2022 to February 2023 in 295,489 unrelated European participants of the UK Biobank (recruited 2006-2010). A weighted genetic risk score from 35 single-nucleotide variants, with weights from the SUNLIGHT Consortium, stood in for lifelong serum 25-hydroxyvitamin D concentration. The primary outcome was sarcopenia; secondary outcomes were grip strength, appendicular lean mass index and gait speed. Participants had a mean age of 56.3 years (SD 8.1), and 139,216 (52.9%) were female.

What it found

The authors’ reported results. Read each estimate with its population and uncertainty.

  1. 1
    Genetically predicted vitamin D and sarcopenia had an L-shaped relation: risk fell quickly as 25(OH)D rose to 20 ng/mL, then levelled off.
  2. 2
    The odds ratio of sarcopenia at 10 versus 20 ng/mL was 1.74 (95% CI 1.17-2.59), meaning higher odds at the lower level.
  3. 3
    The same pattern appeared for each of the sarcopenia indices, which are grip strength, appendicular lean mass index and gait speed. The abstract does not give those estimates.

Limits & uncertainty

  1. 1
    Participants were unrelated people of European ancestry from the UK Biobank, so results may not transfer to other ancestries or populations.
  2. 2
    Mendelian randomization depends on the genetic variants acting only through vitamin D, an assumption the abstract does not test; the authors say randomized trials in people with suboptimal levels are needed to verify causality.
  3. 3
    The genetic score reflects lifelong tendencies, not the effect of raising levels with supplements for a limited time.
  4. 4
    This reading is based on the abstract only.

What to take from it

The study suggests that being low in vitamin D, rather than modestly below the ideal range, may matter most for muscle health, and that raising levels above 20 ng/mL may add little. It cannot show that supplements would prevent sarcopenia. Whether to test or supplement vitamin D is a decision for you and your clinician.

Reading your own data

Vitamin D is a blood test, not something a wearable measures. What you can track is grip strength, walking speed or lean mass, but compare them with your own earlier values using the same method, since consumer scales and devices estimate lean mass imprecisely.

How to read this evidence

The index does not establish a precise design. Read the methods before making causal claims; check population, comparator, outcomes and uncertainty in the source.

Authors’ structured abstract English

The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.

Importance

Vitamin D deficiency is commonly associated with sarcopenia; however, the latest International Clinical Practice Guidelines for Sarcopenia do not recommend vitamin D supplementation for sarcopenia owing to a lack of an apparent therapeutic effect on the indices of sarcopenia among participants with replete vitamin D concentration (ie, 25-hydroxyvitamin D [25(OH)D] level >20 ng/mL) from randomized clinical trials. While there is consensus in all vitamin D guidelines that serum levels of 25(OH)D less than 10 ng/mL should be corrected, approximately 30% of the world population's 25(OH)D levels range from 10 to 20 ng/mL, and it remains unclear whether such suboptimal levels can maintain optimal health, including sarcopenia risk.

Objective

To investigate the association of serum 25(OH)D level, especially suboptimal levels, with sarcopenia risk.

Design, setting, and participants

This genome-wide genetic association study was performed from August 2022 to February 2023 among the 295 489 unrelated European participants from the UK Biobank (2006-2010). Nonlinear and standard mendelian randomization analyses were used to examine the association of serum 25(OH)D concentration with sarcopenia risk.

Exposures

A weighted genetic risk score using 35 unrelated single-nucleotide variants from the UK Biobank and weights from the SUNLIGHT Consortium was selected as an instrumental variable for serum 25(OH)D concentration.

Main outcomes and measures

The primary outcome was sarcopenia, and the secondary outcomes consisted of grip strength, appendicular lean mass index, and gait speed.

Results

The final genetic analyses included 295 489 participants (mean [SD] age, 56.3 [8.1] years; 139 216 female [52.9%]). There was an L-shaped association between genetically predicted serum 25(OH)D concentration and sarcopenia risk. The risk of sarcopenia decreased rapidly as 25(OH)D concentration increased until 20 ng/mL and then leveled off. The odds ratio of sarcopenia for serum 25(OH)D level of 10 vs 20 ng/mL was 1.74 (95% CI, 1.17-2.59). Similar patterns were also observed when the association between serum 25(OH)D concentration and risks of each of the sarcopenia indices were evaluated.

Conclusions and relevance

In this mendelian randomization genetic association study of adults in the UK Biobank, the findings supported a nonlinear association between suboptimal 25(OH)D levels and sarcopenia risk. Randomized clinical trials among participants with suboptimal 25(OH)D levels are required to verify the potential causality.

Sources & attribution

Genetic Variants, Serum 25-Hydroxyvitamin D Levels, and Sarcopenia: A Mendelian Randomization Analysis.

Sha T, Wang Y, Zhang Y, Lane NE, Li C, Wei J, Zeng C, Lei G.

JAMA network open · 2023-08-01

DOI: 10.1001/jamanetworkopen.2023.31558 ↗PubMed · 37647062 ↗Europe PMC · Recorded licence: cc by ↗

Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.

MoveVitals editorial interpretation · educational content · no individual clinical review recorded

Sources checked 2026-11-01

Practical guides

Read in context

·Overview of reviews

ACSM review of 137 reviews: resistance training works, and few programme details matter

The American College of Sports Medicine pooled 137 systematic reviews (over 30,000 healthy adults) and concluded that resistance training beats no exercise for strength, muscle size, power, endurance and several function tests. Few programme details changed results consistently: heavier loads (80% or more of one-repetition maximum) and 2 to 3 sets favoured strength, and at least 10 sets a week favoured muscle size, while training to failure, exercise type and periodization did not. It summarises reviews rather than new trials, gives no pooled effect sizes, and drew mostly on untrained adults and overlapping source trials.

Medicine & Science in Sports & Exercise

In-depth explainersRead study →
·Trial meta-analysis

Nearly every resistance training plan beat no exercise; heavy loads led for strength

In a network meta-analysis of randomised trials in healthy adults (178 studies and 5097 people for strength, 119 studies and 3364 people for muscle size), nearly all resistance training prescriptions beat no exercise. Higher-load, multiset, thrice-weekly training ranked best for strength (standardised mean difference 1.60, 95% credible interval 1.38 to 1.82) and higher-load, multiset, twice-weekly training for muscle size (0.66, 0.47 to 0.85). Most prescriptions could not be statistically separated from each other (the 95% interval contained zero in 91% of the comparisons between them) and risk of bias was moderate to high, so the rankings are tentative.

British Journal of Sports Medicine

In-depth explainersRead study →
·Observational meta-analysis

Muscle-strengthening linked to lower risk of death, heart disease, cancer and diabetes

Pooling 16 prospective cohort studies of adults, people who did muscle-strengthening activity had a 15% lower risk of all-cause mortality (RR 0.85, 95% CI 0.79 to 0.93) and a 17% lower risk of both cardiovascular disease and diabetes (RR 0.83 for each) than people who did none. The pooled mortality curve was lowest at about 40 min/week (RR 0.83), but whether larger amounts help or hurt is unclear. All of this is observational, from mostly US self-reported data, and the authors rated the certainty of evidence as very low for most outcomes.

British Journal of Sports Medicine

In-depth explainersRead study →
·Trial meta-analysis

Protein supplements and weight training: small extra gains, smaller in older adults

Pooling 49 randomised trials with 1,863 healthy adults who did resistance training for at least 6 weeks, protein supplements added 0.30 kg of fat-free mass (95% CI 0.09 to 0.52) and 2.49 kg of one-repetition-maximum strength (0.64 to 4.33) on top of training alone. These gains were small next to the effect of training itself, were weaker with older age, and the suggested plateau near 1.6 g/kg/day was not statistically significant (p=0.079). One author has received funding from the US National Dairy Council, which supported trials in the analysis.

British Journal of Sports Medicine

In-depth explainersRead study →
Strength & muscle →